HC Wainwright Has Weak Outlook for Kairos Pharma Q2 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Stock analysts at HC Wainwright reduced their Q2 2026 earnings estimates for Kairos Pharma in a research report issued on Thursday, May 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.09) per share for the quarter, down from their prior estimate of ($0.08). The consensus estimate for Kairos Pharma’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Kairos Pharma’s Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.37) EPS.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter.

Kairos Pharma Stock Performance

Shares of KAPA opened at $0.48 on Tuesday. The company’s 50 day moving average price is $0.59 and its 200 day moving average price is $0.70. Kairos Pharma has a 52 week low of $0.40 and a 52 week high of $2.11. The company has a market capitalization of $10.28 million, a PE ratio of -1.60 and a beta of 1.51.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC purchased a new position in Kairos Pharma during the third quarter valued at approximately $27,000. Two Sigma Investments LP purchased a new position in Kairos Pharma during the third quarter valued at approximately $54,000. Finally, XTX Topco Ltd grew its position in Kairos Pharma by 290.8% during the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock valued at $34,000 after purchasing an additional 36,086 shares in the last quarter.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical?stage biopharmaceutical company focused on developing small?molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full?length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.